Company Overview
Tandem Diabetes Care, Inc. is a specialized developer and commercializer of advanced technology solutions designed to assist individuals managing diabetes across the United States and international markets. The company operates within the Healthcare sector, specifically focusing on the Medical Devices industry, where it provides critical tools for insulin delivery and automated glucose management. Its operational scale is defined by a market capitalization of $1.70B and an annual revenue of $1.01B over the trailing twelve months, supported by a workforce of 2,500 employees. These financial metrics indicate that the company holds a substantial position within its niche, generating significant top-line revenue while maintaining a valuation that reflects investor expectations for its proprietary hardware and software ecosystem. The flagship t:slim X2 insulin delivery system and the Tandem Mobi insulin pump serve as the core products driving this revenue, establishing the firm as a key player in the broader diabetes care landscape.
Financial Health
The company reported revenue of $1.01B for the trailing twelve months, yet it posted a net income of $-204,710,000 and an EBITDA of $-60,456,000, highlighting a significant disparity between top-line generation and profitability. This substantial gap between revenue and net income reveals a cost structure burdened by high operating expenses or non-operating charges that erode the bottom line despite strong sales performance. Free cash flow stood at $-44,731,124, indicating that the company is currently burning cash rather than generating liquidity from its operations, which constrains its financial flexibility and reliance on external capital sources. The gross margin stands at 53.8%, suggesting that the company retains a healthy portion of revenue after the direct costs of producing its insulin pumps and associated technologies. However, the operating margin of 2.9% and the profit margin of -20.2% demonstrate that overhead costs and other expenses are consuming the majority of the revenue, resulting in a negative overall profitability picture. On the balance sheet, the company holds $292.67M in cash against total debt of $449.38M, resulting in a debt-to-equity ratio of 289.60, which characterizes the entity as highly leveraged and financially strained. The current ratio of 2.55 indicates that the company possesses 2.55 times more current assets than current liabilities, suggesting a theoretically comfortable short-term liquidity position despite the high leverage. Furthermore, the return on equity is -97.9% and the return on assets is -5.3%, metrics that reveal management has been ineffective at generating positive returns on the capital invested in the business.
Valuation Assessment
The company presents a trailing P/E ratio of N/A due to its negative earnings, while the forward P/E is -1011.82, a figure that implies earnings are currently negative and suggests significant uncertainty regarding the trajectory toward profitability in the near term. The price-to-book ratio is 10.92, indicating that the market is valuing the company at nearly 11 times its book value, which suggests a high market premium over the net asset value typically seen in distressed or turnaround situations. Additional valuation metrics include a price-to-sales ratio of 1.67 and an EV/EBITDA of -30.64, which provide alternative perspectives on value that do not rely on earnings but instead focus on sales multiples and enterprise value relative to operating cash generation. The stock has demonstrated significant volatility, trading within a 52-week range bounded by a high of $29.65 and a low of $9.98. Without the specific current share price listed in the available facts to calculate the exact percentage deviation, the price metrics confirm a wide trading band where the stock can experience substantial swings. The beta value of 1.67 indicates that the stock's price volatility is 67% higher than the broader market, making it a high-risk investment that reacts more aggressively to market movements than the average equity.
Growth & Income
Revenue growth over the year-over-year period was 2.7%, while earnings growth is listed as N/A due to the company's negative net income position. Because the company is currently unprofitable, earnings are not growing in a traditional sense relative to revenue, implying that management must focus on cost reduction or margin expansion before earnings growth can be realized. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning it does not distribute cash to shareholders and instead reinvests its limited cash reserves into growth initiatives or operations. The overall growth and income profile is characterized by modest top-line expansion accompanied by significant profitability challenges and a lack of income distribution, positioning the firm as a pure-play growth story that currently requires substantial capital to navigate its path toward sustained profitability.